Collegium Pharmaceutical (NASDAQ:COLL) Given New $36.00 Price Target at Piper Sandler

Collegium Pharmaceutical (NASDAQ:COLL) had its price target lowered by stock analysts at Piper Sandler from $37.00 to $36.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the specialty pharmaceutical company’s stock. Piper Sandler’s price objective points to a potential upside of 15.38% from the company’s previous close.

COLL has been the subject of a number of other research reports. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research note on Friday, January 10th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Finally, StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Collegium Pharmaceutical has an average rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Trading Down 2.9 %

Shares of NASDAQ:COLL opened at $31.20 on Tuesday. Collegium Pharmaceutical has a 12-month low of $28.39 and a 12-month high of $42.29. The company has a market cap of $1.01 billion, a PE ratio of 13.45 and a beta of 0.82. The stock has a 50 day moving average of $31.02 and a 200 day moving average of $34.18. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 27,500 shares of the firm’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the transaction, the executive vice president now owns 119,184 shares of the company’s stock, valued at $3,937,839.36. This trade represents a 18.75 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 3.98% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of hedge funds have recently made changes to their positions in COLL. Sanctuary Advisors LLC raised its holdings in Collegium Pharmaceutical by 5.3% in the fourth quarter. Sanctuary Advisors LLC now owns 18,928 shares of the specialty pharmaceutical company’s stock worth $542,000 after purchasing an additional 952 shares in the last quarter. Rhumbline Advisers grew its position in shares of Collegium Pharmaceutical by 5.8% in the 4th quarter. Rhumbline Advisers now owns 108,228 shares of the specialty pharmaceutical company’s stock worth $3,101,000 after buying an additional 5,920 shares during the last quarter. Meritage Portfolio Management raised its stake in shares of Collegium Pharmaceutical by 5.0% during the 4th quarter. Meritage Portfolio Management now owns 20,755 shares of the specialty pharmaceutical company’s stock worth $595,000 after acquiring an additional 979 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Collegium Pharmaceutical by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock valued at $196,000 after acquiring an additional 642 shares during the last quarter. Finally, Caprock Group LLC boosted its stake in Collegium Pharmaceutical by 6.7% in the fourth quarter. Caprock Group LLC now owns 8,698 shares of the specialty pharmaceutical company’s stock valued at $249,000 after acquiring an additional 543 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.